Q-omics provides the consensus-scored VN1R21P profile across patient tissues and cancer cell-line models. VN1R21P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, VN1R21P is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, VN1R21P RNA expression shows 11,282 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, LUSC, and THYM as cancer lineages where VN1R21P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VN1R21P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VN1R21P survival associations across molecular data types. VN1R21P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VN1R21P RNA expression–survival associations across cancer types. High VN1R21P expression shows unfavorable associations in LIHC, READ, DLBC, ACC and THCA, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for VN1R21P RNA expression.
This table summarizes VN1R21P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for VN1R21P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VN1R21P shows lower tumor expression in PRAD and THCA and higher tumor expression in LUSC and LUAD. The LUSC box plot shows higher VN1R21P RNA expression in tumor versus normal tissue (log2 FC = +0.136, t-test p < 0.001).
This table shows molecular features associated with VN1R21P in patient tissues and cancer cell lines. In patient samples, VN1R21P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
